July 29, 2020 06:37 AM EDT
R&D
Coronavirus

Roche de­clares a PhI­II fail­ure for Covid-19 as the IL-6 re­pur­pos­ing the­o­ry bites the dust

John Carroll

Editor & Founder

An­oth­er big IL-6 drug has failed to move the nee­dle for Covid-19 pa­tients, leav­ing that par­tic­u­lar field of re­pur­posed drug R&D on the ropes for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Is there room for MASH drugs in a GLP-1 world?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times